$0.03—Stale · unknown old
STO • Last print unknown ago
$0.03—Stale · unknown old
Asarina Pharma AB is a biotechnology company focused on developing innovative treatments for rare diseases, particularly in the field of neurology. The company is advancing its lead candidate, a drug for treating a rare form of epilepsy, which has shown promising results in early clinical trials, positioning it uniquely in a niche market with limited competition.
Asarina Pharma primarily generates revenue through grants and funding for clinical trials, as it has not yet commercialized any products. The company benefits from a strong intellectual property portfolio and partnerships with research institutions, which enhance its ability to secure funding.
Progress in clinical trials for lead drug candidate
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or setbacks
Market sentiment towards biotech sector
Regulatory changes affecting drug approval processes
Technological advancements by competitors in epilepsy treatments
Emergence of alternative therapies for epilepsy
Potential for larger pharmaceutical companies to enter the market
High operational losses leading to cash burn
Dependence on external funding sources for R&D
low - As a biotech firm focused on rare diseases, its performance is less correlated with the broader economic cycle and consumer spending.
Interest rates affect the cost of capital for biotech firms, impacting funding availability for R&D. Higher rates could constrain access to financing, which is critical for Asarina's ongoing trials.
minimal - The company has a manageable debt-to-equity ratio of 0.61, indicating limited reliance on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech space.
high - The stock has experienced significant volatility, with a 1-year return of -96.0%.